The marketing authorisation states that nalmefene should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption and be initiated only in patients who continue to have a high drinking risk level 2 weeks after initial assessment.
The costing statement for this guidance estimates that its implementation will be associated with an annual cost of £49,700 per 100,000 population, based on a number of stated assumptions. This is equivalent to £26.4 million for the population of England.